Leading cardiologist to helm wearable sensor research in Ireland

Sarah Sipek | | Cardiovascular Business | Interventional Cardiology

William Wijns, co-director of EuroPCR and chairman of PCR, has joined NUI Galway as a professor of medical devices. He will head the $5 million research project to develop wearable sensors for patients at high risk of heart attacks.

Eight of the world’s top 10 med-tech companies are based in Ireland.

Wijns’ programme of work will focus on interventional cardiology, more specifically on reducing the number of heart attacks in patients.

Wijns’ research focuses on heart attacks and sudden death caused by unexpected blockage of arteries supplying the heart with blood and oxygen. This occurs in people exposed to risk factors such as family history, hypertension, smoking, diabetes or high cholesterol, who exhibit a vulnerable narrowing in the walls of their arteries, without being aware of it.

Click below to read the full story:

Leading cardiology expert to lead €5 million project

Sarah Sipek

Related Content

Angiographic catheters recalled due to safety risk
TAVR patients with moderate or greater TR may face increased risks
Robotic heart surgery represents a key step forward for SS Innovations
Late-breaking clinical trials announced for New York Valves 2025
Next-day discharge after TAVR is still safe when alternative access is required
Q&A: Cardiologist and EARLY TAVR co-author questions study’s execution

Around the web

Health Exec
Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.